Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration

Shinkichi Takamori, Taichi Matsubara, Naoki Haratake, Naoko Miura, Masafumi Yamaguchi, Ryo Toyozawa, Takashi Seto, Kenichi Taguchi, Mitsuhiro Takenoyama

Research output: Contribution to journalArticlepeer-review


Non-small cell lung cancer (NSCLC) patients are sometimes referred for thoracic surgical consultation to address the possibility of resecting second primary lung cancer. We report a case of pulmonary resection for second primary lung adenocarcinoma after 3 cycles of pembrolizumab under circumstances in which the primary metastatic lung adenocarcinoma was controlled. The tumor statuses, including programmed death-ligand 1, epidermal growth factor receptor, and CD8+ tumor-infiltrating lymphocytes, were different between the surgically resected specimen and the previously biopsied sample. Surgery should be considered for second primary NSCLC in cases in which the primary NSCLC are well controlled with immune checkpoint inhibitors.

Original languageEnglish
Pages (from-to)e377-e379
JournalAnnals of Thoracic Surgery
Issue number5
Publication statusPublished - Nov 2020

All Science Journal Classification (ASJC) codes

  • Surgery
  • Pulmonary and Respiratory Medicine
  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Surgically Resected Second Primary Lung Adenocarcinoma After Pembrolizumab Administration'. Together they form a unique fingerprint.

Cite this